Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Scalp Psoriasis Clear all

Completed Phase 4 Interventional Results available

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

NCT05478499

View directory record Official record

Conditions: Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Hot Springs, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 11 more

Source: ClinicalTrials.gov public record

Updated Oct 27, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older

Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Encinitas, California • Fremont, California • San Diego, California + 25 more

Source: ClinicalTrials.gov public record

Updated Dec 20, 2018 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150

View directory record Official record

Conditions: Plaque Psoriasis, Scalp Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 79
States / cities: Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more

Source: ClinicalTrials.gov public record

Updated Sep 11, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Results available

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

NCT02985736

View directory record Official record

Conditions: Psoriasis
Interventions: Topicort Topical Spray; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: East Windsor, New Jersey

Source: ClinicalTrials.gov public record

Updated Apr 8, 2024 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

NCT02038569

View directory record Official record

Conditions: Psoriasis Vulgaris
Interventions: LEO 80185 gel; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more

Source: ClinicalTrials.gov public record

Updated Mar 9, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Accepts healthy volunteers

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

NCT05872256

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: 0.045% Tazarotene/0.01% Halobetasol Lotion; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Source: ClinicalTrials.gov public record

Updated Nov 17, 2023 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

NCT04243486

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: UHE-105, Vehicle; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: San Diego, California • High Point, North Carolina

Source: ClinicalTrials.gov public record

Updated Jul 8, 2020 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Results available

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

NCT03055494

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: Hot Springs, Arkansas • Los Angeles, California • Santa Ana, California + 11 more

Source: ClinicalTrials.gov public record

Updated Mar 9, 2023 · Synced May 21, 2026, 10:11 PM EDT

Not listed Phase 4 Interventional

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

NCT01558310

View directory record Official record

Conditions: Scalp Psoriasis, Plaque Psoriasis
Interventions: Ustekinumab, Placebo; Drug
Lead sponsor: Paul Steven Yamauchi, MD, PhD; Individual
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Santa Monica, California

Source: ClinicalTrials.gov public record

Updated Jul 17, 2012 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Source: ClinicalTrials.gov public record

Updated Mar 18, 2019 · Synced May 21, 2026, 10:11 PM EDT

Suspended Phase 2 Interventional

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

NCT01368887

View directory record Official record

Conditions: Psoriasis
Interventions: DPS-102, Vehicle / Placebo, Calcipotriol Monotherapy, Nicotinamide Monotherapy; Drug · Other
Lead sponsor: DermiPsor, Ltd.; Industry
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Brockton, Massachusetts

Source: ClinicalTrials.gov public record

Updated Jun 7, 2011 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Results available

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223

View directory record Official record

Conditions: Genital Psoriasis, Scalp Psoriasis
Interventions: Risankizumab, Placebo for Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more

Source: ClinicalTrials.gov public record

Updated Feb 23, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

NCT01083758

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel); Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 10, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

NCT03897088

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: PART 1: Double-blind Placebo-controlled, PART 2: Double-blind Active Treatment Extension; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older

Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: Encinitas, California • Fountain Valley, California • Fremont, California + 15 more

Source: ClinicalTrials.gov public record

Updated May 30, 2023 · Synced May 21, 2026, 10:11 PM EDT

Active, not recruiting Phase 3 Interventional

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older

Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Source: ClinicalTrials.gov public record

Updated Mar 12, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299

View directory record Official record

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Apremilast, Etanercept, Placebo tablet, Placebo injection; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 31
States / cities: Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more

Source: ClinicalTrials.gov public record

Updated Mar 14, 2022 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

NCT01139580

View directory record Official record

Conditions: Psoriasis
Interventions: Calcipotriene Foam, Vehicle Foam; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older

Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 26
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 22 more

Source: ClinicalTrials.gov public record

Updated Jan 17, 2017 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

NCT05028582

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: Roflumilast Foam 0.3%, Vehicle Foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 36
States / cities: Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more

Source: ClinicalTrials.gov public record

Updated Jul 16, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Roflumilast foam 0.3%, Vehicle foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 31
States / cities: Rogers, Arkansas • Fremont, California • San Diego, California + 27 more

Source: ClinicalTrials.gov public record

Updated Oct 25, 2022 · Synced May 21, 2026, 10:11 PM EDT

Recruiting Phase 1 Interventional

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

NCT07340216

View directory record Official record

Conditions: Psoriasis
Interventions: ARQ-154 Foam 0.3%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 2 Years to 12 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Bryant, Arkansas • Miami Lakes, Florida • Meridian, Idaho + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 13, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172

View directory record Official record

Conditions: Psoriasis
Interventions: Apremilast, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 43
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more

Source: ClinicalTrials.gov public record

Updated May 28, 2024 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353

View directory record Official record

Conditions: Scalp Psoriasis
Interventions: Calcipotriene and betamethasone suspension, Taclonex, Placebo; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more

Source: ClinicalTrials.gov public record

Updated Mar 6, 2018 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162

View directory record Official record

Conditions: Psoriasis
Interventions: Calcipotriene/betamethasone gel and ointment; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Feb 23, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471

View directory record Official record

Conditions: Psoriasis
Interventions: Apremilast, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more

Source: ClinicalTrials.gov public record

Updated May 12, 2020 · Synced May 21, 2026, 10:11 PM EDT